conclude that up to the highest exposure tested (10 mg/kg infused every two weeks) no dose limiting toxicities were observed. Intrapatient dose escalation studies were used to gain sufficient understanding of pembrolizumab pharmacokinetic (PK) properties and build a predictive model. Importantly, the authors used an ex vivo read-out of peripheral blood T cell activation to establish a PK-PD (pharmacodynamic response) relationship, focused on identifying an optimal pembrolizumab dose level and schedule achieving maximal immunological activity. The assay deployed involved the use of Staphyloccus enterotoxin B (SEB) to stimulate a fraction of blood-derived T cells to produce IL-2. In healthy donor and cancer patient whole blood this response was known to be modulated in a dose-dependent fashion by antibodies targeting PD-1, PD-L1 and CTLA-4. Patnaik et al. (1) further expanded on these observations by testing the ex vivo SEB response in patients dosed with pembrolizumab essentially establishing a longitudinal data set explaining optimal PD-1 engagement in relation to dose. In addition, the authors report on mouse studies relating blood antibody levels to intratumoral concentrations, leading to a rather precise prediction that a schedule of 2 mg/kg q3w achieves maximal engagement in the tumor compartment. Enormous attention is devoted to further pinpointing the precise mechanism-ofaction of these checkpoints inhibitors. That knowledge seems key to enable selection of responder patients, optimal combination with other drugs, and to identify alternative means to enhance productive tumor immunity. Thus far, we have learned that successful tumor rejection involves effector T cells (both CD8 and CD4) and IFNγ, and is inhibited by the This publication of first-in-human study of pembrolizumab in advanced cancer patients (1) follows after the publication of pivotal data in ipilimumab-refractory melanoma (6, 12) . In an interesting approach, after completing the dose-escalation phase pembrolizumab was tested in a variety of expansion cohorts constituting an unusually large 
